ARTICLE | Clinical News

Cinquil reslizumab: Phase II data

March 1, 2010 8:00 AM UTC

Data from a double-blind, North American Phase II trial in 106 patients showed that 3 mg/kg of Ception's IV Cinquil once every 28 days for 4 cycles missed the primary endpoint of significantly improving asthma control as measured by change in ACQ score at week 15 vs. placebo (p=0.054). Cinquil did meet the secondary endpoints of a significant reduction in sputum eosinophil counts vs. placebo (p=0.006) and a significant improvement in FEV1 and FVC vs. placebo (p=0.002 and p=0.004, respectively). Additionally, fewer patients treated with Cinquil experienced clinical asthma exacerbations compared to placebo. In a subset of patients with both asthma and nasal polyps (n=38), Cinquil significantly improved ACQ score (p=0.011) and FEV1 (p=0.046) vs. placebo. Cinquil was well tolerated. ...